TD Cowen analyst Tara Bancroft has maintained their bullish stance on XNCR stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tara Bancroft’s rating is based on the promising data from Xencor’s XmAb942, which showed sustained TL1A suppression for over 16 weeks without the presence of anti-drug antibodies. This suggests a competitive advantage in terms of potency and convenience over current Phase II/III competitors. The initiation of the Phase IIb UC trial further supports confidence in its potential efficacy.
Additionally, Xencor’s strategic advancements, including the upcoming data release for ‘819 in ccRCC and the initiation of the Phase Ib/IIa trial for plamo in RA, indicate a robust pipeline. The company’s recent Phase IIb XENITH-UC trial initiation for XmAb942, targeting patients with moderate-to-severe UC, aims to demonstrate improved outcomes due to consistent drug exposure, setting it apart from existing treatments. These factors collectively underpin the Buy rating given by Tara Bancroft.
In another report released yesterday, William Blair also maintained a Buy rating on the stock with a $0.00 price target.